Gain Therapeutics (GANX) announced the start of the Phase 1b extension study allowing participants to continue treatment for an additional nine months. More than half of the participants have agreed to continue treatment. The Phase 1b study enrolled 21 participants and is expected to complete in December 2025. Early data from the Phase 1b study will be presented on October 7, 2025, at the International Congress of Parkinson’s Disease and Movement Disorders(R) in Honolulu, HI. Additional 90-day analysis from participants enrolled as of June 30, 2025, including functional changes scored according to the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as well as biomarker data from cerebrospinal fluid and blood, will be available as expected in Q4 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Positive Buy Rating for Gain Therapeutics Driven by Promising Clinical Trial Developments and Strong Financial Outlook
- Promising Developments and Regulatory Milestones Bolster Buy Rating for Gain Therapeutics
- Gain Therapeutics receives Australian approval of Phase 1b dosing extension
- Buy Rating Reaffirmed for Gain Therapeutics Amid Promising Clinical Developments and Strong Financial Positioning
- Gain Therapeutics Reports Q2 2025 Financial Results